Drug-makers could one day make products faster because of a $2.5 million National Science Foundation (NSF)-funded project now underway at the University of Maryland, Baltimore (UMB) and three other sites.
The cyber-infrastructure project goes to the heart of a current dilemma facing scientists trying to conduct efficient drug discovery and development from the massive data available on the human genome, says Alexander MacKerell, Grollman-Glick Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy.
Scientists who look for new therapeutic drug opportunities from human gene and protein data have, in turn, created a “huge number of computational tools based on the mathematical models and parameters to biological molecules,” says MacKerell, who is director of the Computer-Aided Drug Design Center at the School of Pharmacy and principal investigator for the project. But, he says, such software tools are not one-size-fits-all. They are designed for different categories of molecules.
“Right now it is very tedious and time consuming to set up these mathematical models and parameters for the new molecules. Our cyber infrastructure will make this much faster. We are going to put the parameter engine in place to do the work for the scientist.”
Also funded for the cyber-infrastructure project are the Universities of Kentucky, Florida, and Illinois. Across the four universities, the project will also have applications in facilitating the design of electronics and the study of a wide range of material science and biological systems at the most basic level, in addition to drug design applications.
The project is aimed toward putting the parameter engine online. Researchers will go to the Internet, enter their drug molecule, and get the best model and the correct parameters for making their investigation more efficient. The proposed engine will provide an open architecture for obtaining and testing parameters under various conditions.
Ordinarily, once a drug company identifies a new drug candidate for the treatment of a particular medical problem, the next step is optimizing the drug candidate to improve its therapeutic potential. This is a huge task that involves testing hundreds of molecules, a task that can be facilitated using computational tools, says MacKerell. “We are trying to allow for computational tools to be rapidly applied to large numbers of molecules. We want to automate this process. To do so will allow computational scientists to work with biologists, thereby decreasing the time and cost required to develop new drug candidates.”
Also, the project will include annual workshops for education and outreach.
The basis for the Computer-Aided Drug Design Center is to ease the discovery of novel therapeutic agents that combines rational drug design methods with chemistry and structural biology. The computer-aided drug design approach allows researchers to use information available in 3-D structures of biological target molecules, which may be associated with human diseases, to identify chemicals that have a great potential for binding to those target molecules. Chemical compounds developed by such steps can often be developed into research tools and/or therapeutic agents. The NSF cyber-infrastructure project will help make this potential a reality.
Robert Latour, PhD, the McQueen-Quattlebaum Professor of Bioengineering at Clemson University, wrote a letter to the NSF supporting the project “because this is very important for a much broader spectrum of applications. It has enormous potential down the road to design things at the atomic level,” he said. Latour uses the same computational chemistry technology to simulate the interactions between biological molecules, such as proteins, and synthetic materials at the atomic level, aimed toward developing more accurate devices to detect biowarfare agents, more biocompatible implants for the human body, and other bionanotechnology applications.
Steve Berberich | Newswise Science News
Further reports about: > CHEMISTRY > Computational > Computer-Aided Drug Design Center > Cyber Chemistry > Design > Design Thinking > Drug Delivery > Drug-Making > Scientist > atomic level > biocompatible implants > biological molecules > biological system > bionanotechnology applications > computational chemistry technology > computational tools > cyber-infrastructure project > human genome > material science > therapeutic
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine